Published in TB and Outbreaks Week, July 26th, 1999
Over the past few years much tuberculosis research has been aimed at the identification of individual mycobacterial antigens involved in the immune response to tuberculosis, with the aim of developing subunit vaccines. An alternative strategy to the development of novel vaccines consists of constructing mutant strains of mycobacteria that are rationally attenuated.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.